Osimertinib-Induced Toxic Epidermal Necrolysis  – A Case Report

Crvenkova, Simonida; Popova, Maja; Crvenkova, Labina; Lazarevska, Antonija

doi:10.2478/prilozi-2024-0025

Abstract

Purpose

To investigate the rare side effects of Osimertinib in a case of toxic epidermal necrosis.

Case Presentation

We report on a case of a 44-year old woman with lung adenocarcinoma harboring an EGFR-sensitizing mutation who was treated with Osimertinib as the second-line treatment. Ten days after Osimertinib initiation, a diffuse erythematous rash rapidly spread over the patient’s trunk along with vesicles and purpuric macules; furthermore, she developed erythema and exfoliation on the face and trunk and severe mucositis. Toxic epidermal necrolysis (TEN) is life-threatening dermatologic adverse event, caused by a delayed-type drug hypersensitivity reaction. Although skin toxicity is common during treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), Osimertinib-associated TEN is very rare.

Results

Treatment with systemic steroids and immunoglobulin as well as supportive treatment led to an improvement of her general wellbeing, followed by a remarkable recovery.

Conclusions

Although the clinical use of Osimertinib is becoming widespread, the side effects may not be fully understood. Clinicians should indeed pay more attention to the occurrence of side effects and be prepared to deal with them in timely manner.

References

Lynch, T.J.; Bell, D.W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R.A.; Brannigan, B.W.; Harris, P.L.; Haserlat, S.M.; Supko, J.G.; Haluska, F.G.; et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350, 2129–2139.
Search in Google Scholar Back to article
Paez, J.G. EGFR Mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004, 304, 1497–1500.
Search in Google Scholar Back to article
Mok, T.S.; Wu, Y.L.; Ahn, M.J.; Garassino, M.C.; Kim, H.R.; Ramalingam, S.S.; Shepherd, F.A.; He, Y.; Akamatsu, H.; Theelen, W.S.; et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N. Engl. J. Med. 2016,
Search in Google Scholar Back to article
Lerch, M.; Mainetti, C.; Beretta-Piccoli, B.T.; Harr, T. Current perspectives on stevens-johnson syndrome and toxic epidermal necrolysis. Clin. Rev. Allergy Immunol. 2017, 54, 147–176.
Search in Google Scholar Back to article
Lin, Y.T.; Chu, C. Osimertinib-induced Stevens-Johnson syndrome in a patient with EGFR T790M mutation-positive non-small cell lung cancer. Lung Cancer 2019, 129, 110–111.
Search in Google Scholar Back to article
Ko TM, et al. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol. 2011;128(6):1266–76.
Search in Google Scholar Back to article
De Araujo E, et al. Death ligand TRAIL, secreted by CD1a + and CD14 + cells in blister fluids, is involved in killing keratinocytes in toxic epidermal necrolysis. Exp Dermatol. 2011; 20(2): 107–12.
Search in Google Scholar Back to article
Mok TS, Wu YL, Ahn MJ et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 2017; 376: 629–640.
Search in Google Scholar Back to article
Ohe, Y.; Imamura, F.; Nogami, N.; Okamoto, I.; Kurata, T.; Kato, T.; Sugawara, S.; Ramalingam, S.S.; Uchida, H.; Hodge,R.; etal. Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset. Jpn. J. Clin. Oncol. 2019, 49, 29–36.
Search in Google Scholar Back to article
Yang JC, Ahn MJ, Kim DW et al. Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension compo nent. J Clin Oncol 2017; 35: 1288–1296.
Search in Google Scholar Back to article
Goss G,Tsai CM, Shepherd FA et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): A multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 2016; 17: 1643–1652.
Search in Google Scholar Back to article
Soria JC, Ohe Y,Vansteenkiste J et al. Osimertinib in untreated EGFR-mutated advanced non small-cell lung cancer. N Engl J Med 2017; 378: 113–125.
Search in Google Scholar Back to article
Kozuki, T. Skin problems and EGFR-tyrosine kinase inhibitor. Jpn. J. Clin. Oncol. 2016, 46, 291–298.
Search in Google Scholar Back to article
Chung,W.H.; Hung, S.I.; Hong, H.S.; Hsih, M.S.; Yang, L.C.; Ho, H.C.; Wu, J.Y.; Chen, Y.T. Medical genetics: Amarker for Stevens-Johnson syndrome. Nature 2004, 428, 486.
Search in Google Scholar Back to article
Khoo, A.; Foo, C. Toxic epidermal necrolysis in a burns centre: A 6-year review. Burns 1996, 22, 275–278.
Search in Google Scholar Back to article
Roujeau, J.C.; Kelly, J.P.; Naldi, L.; Rzany, B.; Stern, R.S.; Anderson, T.; Auquier, A.; Bastuji-Garin, S.; Correia, O.; Locati, F.; et al. Medication use and the risk of stevens–johnson syndrome or toxic epidermal necrolysis. N. Engl. J. Med. 1995, 333, 1600–1608.
Search in Google Scholar Back to article
Lonjou, C.; Thomas, L.; Borot, N.; Ledger, N.; De Toma, C.; LeLouet, H.; Graf, E.; Schumacher, M.; Hovnanian, A.; Mockenhaupt,M.; etal. AmarkerforStevens-Johnsonsyndrome: Ethnicitymatters. Pharm. J. 2006, 6, 265–268.
Search in Google Scholar Back to article
Wang, J.; Cheng, X.; Lu, Y.; Zhou, B. A case report of toxic epidermal necrolysis associated with AZD-9291. Drug Des. Dev. Ther. 2018, 12, 2163–2167.
Search in Google Scholar Back to article
Huang, J.J.; Ma, S.-X.; Hou, X.; Wang, Z.; Zeng, Y.D.; Qin, T.; Dinglin, X.X.; Chen, L.K. Toxic epidermal necrolysis related to AP (pemetrexed plus cisplatin) and gefitinib combination therapy in a patient with metastatic non-small cell lung cancer. Chin. J. Cancer 2015, 34, 94–98
Search in Google Scholar Back to article
Doesch, J.; Debus, D.; Meyer, C.; Papadopoulos, T.; Schultz, E.S.; Ficker, J.H.; Brueckl, W. Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient. Lung Cancer 2016 95, 35–38.
Search in Google Scholar Back to article
Otsuka,T; Tanaka,A.;Azukizawa,H.; Sasaki,S.; Ishijima,M.; Matsuki,T.; Osa,A.; Nakatani,T.; Kuroyama,M.; Hirata, H.; et al. Successful treatment with gefitinib after Stevens–Johnson syndrome associated with afatinib therapy in apatient with adenocarcinoma of the lung. Int. Cancer Conf. J. 2016, 6, 38–41
Search in Google Scholar Back to article
Rittberg R, Ho C, Wang Y. Acute Onset of a Life-Threatening Skin Toxicity Due to Osimertinib: Severe Psoriasis Versus Toxic Epidermal Necrolysis Cureus. 2022 Apr 26; 14(4): e24513.
Search in Google Scholar Back to article
Yunhua Xu,, Yong Li, Jie Luo and Rong Tang Osimertinib-induced Keratitis and Secondary Toxic Epidermal Necrotic Drug Eruption- A Case Report and Literature Review Current Drug Safety, 2024, 19, 309–312.
Search in Google Scholar Back to article

Osimertinib-Induced Toxic Epidermal Necrolysis – A Case Report

Abstract

Purpose

Case Presentation

Results

Conclusions

Paradigm

My account